Albumedix
Recombinant human albumin-based solutions for advanced therapies.
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 1 % | 37 % | (2 %) | 2 % | (14 %) | 21 % | 13 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 10 % | 9 % | 23 % | 32 % | 28 % | 25 % | 7 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | 6 % | 19 % | 26 % | 21 % | 17 % | 2 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Founded in 1984 and headquartered in Nottingham, UK, Albumedix is a biotechnology company specializing in recombinant human albumin-based solutions. In August 2022, the life science group Sartorius acquired Albumedix for approximately £415 million, integrating it into its Bioprocess Solutions division. The acquisition aimed to strengthen Sartorius' portfolio of solutions for advanced therapies, particularly within its cell culture media business. Following the acquisition, the Nottingham facility was designated a center of excellence for GMP-compliant production and innovation of critical raw materials.
The company's core business revolves around providing animal-origin-free recombinant human albumin, a critical component for the biopharmaceutical industry. This is used as an additive to cell culture media and for the stabilization of vaccines and viral therapies. Albumedix's product portfolio includes Recombumin®, a range of high-quality recombinant human albumins that serve as multifunctional excipients and raw materials in the development and manufacturing of advanced therapies, including cell and gene therapies. The company also offers a drug-enhancing technology platform called Veltis®. These products address the increasing regulatory requirements and rising demand for high-purity, consistent, and safe materials in biopharmaceutical production.
Albumedix serves the biopharmaceutical and life sciences sectors, providing critical materials for the production of vaccines, viral therapies, and other complex biopharmaceuticals. The business model is based on the development, manufacturing, and supply of these high-value albumin products and technologies to pharmaceutical and medical device companies worldwide. When it was acquired in 2022, the company had over 100 employees and was expected to generate revenue of approximately £33 million for that year. Jonas S. Møller, who was the CEO at the time of the acquisition, continued to lead the business unit.
Keywords: recombinant human albumin, advanced therapies, cell culture media, vaccine stabilization, biopharmaceutical excipients, animal-free components, viral therapies, GMP manufacturing, bioprocess solutions, critical raw materials, drug delivery, formulation excipients, Recombumin, Veltis, Sartorius, biomanufacturing, life sciences, cell therapy, gene therapy, protein stabilization